Evidence map›Paper›PMID 21475970›Full record

Trial reportPsychopharmacology2011

Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia.

Jennifer W Tidey, Damaris J Rohsenow, Gary B Kaplan, Robert M Swift, Netesha Reid

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00136760 (Incentives Plus Bupropion for Smoking in Schizophrenics), which is not on this map. Cited by 40 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 9 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00136760 phase2completednot on this map

Incentives Plus Bupropion for Smoking in Schizophrenics

TypeinterventionalSponsorBrown UniversityRan2003 to 2009Enrolled57ConditionsSchizophrenia and Disorders With Psychotic Features, Tobacco Use DisorderArmsBupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 9 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Guideline
  2. Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2020
    Pooled it
  3. Pooled it
  4. Incentives for smoking cessation.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Financial Incentives for Smoking Abstinence in Homeless Smokers: A Pilot Randomized Controlled Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018
    Trial
  15. Trial
  16. Antidepressants for smoking cessation.The Cochrane database of systematic reviews · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jennifer W TideyCenter for Alcohol and Addiction Studies, Brown University, Box S-121-5, Providence, RI 02912, USA. Jennifer_Tidey@brown.edu
Damaris J Rohsenow
Gary B Kaplan
Robert M Swift
Netesha Reid
Brown University · USBoston University · USProvidence VA Medical Center · US

Funding

Incentives Plus Bupropion for Smoking in SchizophrenicsR01DA017566 · NIDA · BROWN UNIVERSITY · PI TIDEY, JENNIFER W. · 2003 to 2006
$1.3M
NIDA NIH HHS R01 DA017566NIDA NIH HHS R01-DA17566
6 · The paper itself

Abstract

rationaleIndividuals with schizophrenia have high smoking-related morbidity and mortality rates and need powerful and innovative smoking cessation interventions.

objectivesThis proof-of-concept study investigated the feasibility and initial efficacy of combining a contingency management intervention with bupropion to reduce smoking in people with schizophrenia.

methodsUsing a double-blind, placebo-controlled, between-groups design, 57 non-treatment-seeking participants were randomized to receive 300 mg/day bupropion or placebo. One week later, participants were randomized to a contingency management (CM) intervention in which reductions in urinary cotinine levels were reinforced, or a non-contingent reinforcement (NR) condition in which session attendance was reinforced, regardless of cotinine level. Over the 22-day study period, participants visited the laboratory approximately three times per week to provide urine samples for analysis of cotinine levels, to give breath samples for analysis of carbon monoxide (CO) levels, and to report number of cigarettes smoked per day, nicotine withdrawal symptoms, cigarette craving, and psychiatric symptoms.

resultsCotinine and CO levels significantly decreased during the study period in participants randomized to the CM condition, but not the NR condition. Bupropion did not reduce cotinine levels or increase the efficacy of CM. Cigarette craving and psychiatric symptom levels significantly decreased during the study in all groups.

conclusionsThe results of this study indicate the efficacy and feasibility of this CM intervention for reducing smoking in individuals with schizophrenia.

Indexed as

Behavior TherapySchizophreniaAdultBehavior, AddictiveBreath TestsBupropionCarbon MonoxideCombined Modality TherapyCotinineDiagnosis, Dual (Psychiatry)Double-Blind MethodFemaleHumansMalePatient DropoutsReinforcement, PsychologyBupropionCarbon MonoxideCotinine

Identifiers

PMID21475970
PMCPMC3685403
OpenAlexW1986563216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.